Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

Abstract

The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11-25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06 microg/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06 microg/L had a day-100 all-cause mortality rate of 7% (P < 0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06 microg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.

• Authors: Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, Nelson Leung, Mark Litzow
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 49 Issue 1 Pg. 36-41 (Jan 2008) ISSN: 1029-2403 [Electronic] United States
• PMID: 18203009 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• Immunoglobulin Light Chains
• Troponin T

Topics

• Adult
• Aged
• Amyloidosis (diagnosis, mortality, therapy)
• Biomarkers
• Cause of Death
• Electrocardiography
• Female
• Hematopoietic Stem Cell Transplantation (mortality)
• Humans
• Immunoglobulin Light Chains
• Male
• Middle Aged
• Patient Selection
• Predictive Value of Tests
• Prognosis
• Troponin T (blood)